Trial Profile
Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 30 Dec 2010 Trial location (Mexico) identified as reported by ClinicalTrials.gov.
- 19 Mar 2009 Status changed from active, no longer recruiting to completed.
- 06 Feb 2009 New trial record